Dawn Zapinski, MD
Neurology · Franklin, INNPI 1720086739
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $575 and has fallen 86.1% since, to $80 in 2025. That places this record below the midpoint for neurology clinicians in IN, where the typical reported total is $1,614.
Across 54 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$274
- Supernus Pharmaceuticals, Inc.$258
- AbbVie$204
- Kyowa Kirin, Inc.$118
- Biohaven Pharmaceutical Holding Company Ltd.$98
- Novo Nordisk$95
- plus $448 from 16 others
Across 6 payments — averaging $3777.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$19K
- Teva Pharmaceuticals USA, Inc.$4K
What the payments were for
- Food & beverage$1,496100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 9 | $274 |
| Supernus Pharmaceuticals, Inc. | 14 | $258 |
| AbbVie | 4 | $204 |
| Kyowa Kirin, Inc. | 1 | $118 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $98 |
| Novo Nordisk | 7 | $95 |
| Amgen | 1 | $95 |
| Biohaven Pharmaceuticals, Inc. | 1 | $95 |
| Livanova USA, Inc. | 2 | $45 |
| Sanofi Pasteur Inc. | 2 | $27 |
| Lilly USA, LLC | 1 | $23 |
| Nalpropion Pharmaceuticals LLC | 1 | $22 |
| Abbott | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Medtronic | 1 | $15 |
| GSK | 1 | $15 |
| Pfizer | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Biogen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOURIANZ$118
How this compares
$1,496 in reported general payments places this provider in the 45th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 14 | $203,402 |
| AubagioTeriflunomide | 11 | $99,193 |
| Glatiramer Acetate | 18 | $37,714 |
| Nurtec OdtRimegepant Sulfate | 15 | $20,692 |
| UbrelvyUbrogepant | 15 | $17,014 |
| QuliptaAtogepant | 12 | $12,634 |
| Lamotrigine ErLamotrigine | 26 | $9,051 |
| Lacosamide | 117 | $8,948 |
| Rivastigmine | 29 | $5,639 |
| Memantine Hcl | 181 | $5,410 |
| Ropinirole ErRopinirole Hcl | 34 | $5,340 |
| Pregabalin | 108 | $4,848 |
| Levetiracetam | 147 | $4,823 |
| DilantinPhenytoin Sodium Extended | 14 | $4,439 |
| Duloxetine Hcl | 130 | $3,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $274 | $99,19311 claims |
| AbbVieUbrelvy, Qulipta | $204 | $29,64827 claims |
| PfizerNurtec Odt, Dilantin | $15 | $25,13229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 308 neurology providers in Indiana.
Other neurology in Franklin
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Ajay GuptaFort Wayne$411K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
- Marlene BultemeyerFort Wayne$277K
- Jerry SmarttCarmel$254K
- Andrea HallerFort Wayne$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.